TTY Biopharm Co Ltd Cash Flow Conversion Efficiency
TTY Biopharm Co Ltd cash flow conversion efficiency. Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has a cash flow conversion efficiency ratio of 0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$654.16 Million ≈ $20.61 Million USD) by net assets (NT$7.40 Billion ≈ $233.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TTY Biopharm Co Ltd (2017–2025)
Cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2025. This chart illustrates how TTY Biopharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for TTY Biopharm Co Ltd for real-time trading data and today's change.
TTY Biopharm Co Ltd Cash Flow Conversion Ratio Explained
TTY Biopharm Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TTY Biopharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TTY Biopharm Co Ltd ranked by their cash flow conversion efficiency. Also see 4105 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mensch und Maschine Software SE
F:MUM
|
0.000x |
|
Shenzhen Centralcon Investment Holding Co Ltd
SHE:000042
|
0.485x |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
0.016x |
|
Qingdao Citymedia Co Ltd
SHG:600229
|
0.000x |
|
Yunnan Coal & Energy Co Ltd
SHG:600792
|
0.097x |
|
Alligo AB Series B
ST:ALLIGO-B
|
0.053x |
|
Ponsse Oyj 1
HE:PON1V
|
-0.035x |
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
0.052x |
Annual Cash Flow Conversion Efficiency for TTY Biopharm Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2025. Review how much free cash does TTY Biopharm Co Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$8.05 Billion ≈ $253.66 Million |
NT$1.76 Billion ≈ $55.51 Million |
0.219x | +21.80% |
| 2024-12-31 | NT$7.51 Billion ≈ $236.64 Million |
NT$1.35 Billion ≈ $42.51 Million |
0.180x | +7.70% |
| 2023-12-31 | NT$6.51 Billion ≈ $204.98 Million |
NT$1.09 Billion ≈ $34.19 Million |
0.167x | -15.86% |
| 2022-12-31 | NT$6.23 Billion ≈ $196.38 Million |
NT$1.24 Billion ≈ $38.93 Million |
0.198x | -8.99% |
| 2021-12-31 | NT$5.77 Billion ≈ $181.70 Million |
NT$1.26 Billion ≈ $39.58 Million |
0.218x | +151.55% |
| 2020-12-31 | NT$6.08 Billion ≈ $191.49 Million |
NT$526.35 Million ≈ $16.58 Million |
0.087x | -55.84% |
| 2019-12-31 | NT$6.17 Billion ≈ $194.36 Million |
NT$1.21 Billion ≈ $38.12 Million |
0.196x | +16.74% |
| 2018-12-31 | NT$6.39 Billion ≈ $201.37 Million |
NT$1.07 Billion ≈ $33.83 Million |
0.168x | +3.03% |
| 2017-12-31 | NT$6.11 Billion ≈ $192.55 Million |
NT$996.52 Million ≈ $31.40 Million |
0.163x | -- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more